Benzinga Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action
The FDA delays its decision on Disc Medicine's rare disease drug bitopertin, raising review questions. Analysts say the setback is likely minor. read more
The FDA delays its decision on Disc Medicine's rare disease drug bitopertin, raising review questions. Analysts say the setback is likely minor. read more